Arcus Biosciences. has been granted a patent for compounds that inhibit HIF-2a, detailed in a specific structural formula. The patent includes compositions of these compounds and outlines methods for their use in treating various diseases and disorders. GlobalData’s report on Arcus Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arcus Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Arcus Biosciences's grant share as of July 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12071411B2 outlines a novel compound or its pharmaceutically acceptable salts, characterized by a specific chemical structure defined in Formula I. The claims detail various configurations of the compound, including the selection of substituents and their positions, which can include halogens, hydroxyl groups, and alkyl chains. The patent specifies that the compound can have multiple variations based on the values of parameters such as n and m, as well as the nature of substituents R1, R2, R3, and R4. These variations allow for a diverse range of chemical entities that may possess unique therapeutic properties.
Additionally, the patent claims encompass a pharmaceutical composition that includes the aforementioned compound and a suitable excipient, as well as methods for treating diseases associated with HIF-2a, particularly von Hippel-Lindau (VHL) disease and various cancers. The claims specify that the treatment can target conditions such as renal cell carcinoma and central nervous system hemangioblastomas, among others. Furthermore, the patent allows for the potential combination of the compound with other therapeutic agents, including tyrosine kinase inhibitors and immune checkpoint inhibitors, to enhance treatment efficacy. This comprehensive approach highlights the compound's potential utility in addressing a range of medical conditions, particularly those related to cancer.
To know more about GlobalData’s detailed insights on Arcus Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
